Decathlon Capital backs neurodegenerative diagnostics firm Amprion

Decathlon Capital Partners has made a growth investment in Amprion Inc, a San Diego diagnostics company focused on neurodegenerative disorders, according to PE Hub. The size of the investment and other financial terms were not disclosed.

PE Hub reported that the capital will be used to support expansion of Amprion’s diagnostic testing capacity. The company’s testing work covers neurodegenerative diseases including Parkinson’s disease, Lewy body dementia and Alzheimer’s disease.

The transaction gives Amprion additional funding for capacity growth rather than a disclosed change of control. In a growth investment, capital is typically directed toward scaling an existing business, and in this case PE Hub identified diagnostic testing capacity as the stated area of support.

Company background

Amprion is based in San Diego and was founded in 2007, according to PE Hub. Russ Lebovitz serves as the company’s chief executive officer.

The company operates in a segment of healthcare where diagnostic infrastructure can affect how quickly and broadly clinicians and researchers obtain testing for neurological conditions. PE Hub did not disclose details on Amprion’s current test volumes, customer base or planned capacity increase.

Decathlon Capital Partners’ investment adds to private capital activity in healthcare services and diagnostics, where funding is often used to expand laboratory capacity, commercial reach or operational infrastructure. PE Hub did not report whether other investors participated in the transaction.

No additional deal terms, valuation, ownership stake or governance arrangements were disclosed.

This story draws on original reporting from PE Hub.